Nintedanib Dose Reductions in IPF May Do No Harm

Patients with idiopathic pulmonary fibrosis who required dose reductions had similar all-cause mortality and death rates vs patients on the full dose.

Related Keywords

Hawaii ,United States ,Mayo Clinic In Rochester ,Minnesota ,Honolulu ,Misbah Baqir ,Lakes Foundation ,American College Of Chest Physicians ,Andrew Limper ,Mayo Clinic ,American College ,Chest Physicians ,Optumlabs Data Warehouse ,Medscape Medical News ,Three Lakes ,Nintedanib Dosing ,Clinical Outcomes ,Real World ,Presented October ,Idiopathic Pulmonary Fibrosis ,Lung Fibrosis ,Pulmonary Fibrosis ,Ibrosis Pulmonary ,Adverse Events Pharmacology ,Chronic Disease ,Chronic Illness ,Interstitial Lung Disease ,Adverse Effects ,Side Effects ,Lung ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Systemic Sclerosis ,Diffuse Scleroderma ,Diarrhea ,Patient Safety ,Scleroderma ,Crest Syndrome ,Toxico ,